In fact, among patients with a recent myocardial infarction and an elevated high sensitivity C-reactive protein (≥ 2.0 mg%), the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) trial demonstrated that inhibition of Interleukin-1β (IL-1β) reduces the composite of adverse vascular events and mortality.42 The gene discussed is IL1B; the disease is myocardial infarction.